диссертации / 122
.pdf121
145.Nienhuis, R. L. F. New Serum Factor in Patients with Rheumatoid Arthritis: The Antiperinuclear Factor/ R. L. F. Nienhuis, E. Mandema, C. Smids // Ann. Rheum. Dis. - 1964. - Vol. 23. - № 4. - P. 302 – 305.
146.Niewold, T. Anti-CCP antibody testing as a diagnostic and prognostic tool in rheumatoid arthritis/ T. Niewold, M. Harrison, S. Paget // Q. J. Med. - 2007. - Vol.
100.- P.193 – 201.
147.Nijenhuis, S. Autoantibodies to citrullinated proteins in rheumatoid arthritis: clinical performance and biochemical aspects of an RA-specifi c marker/ S. Nijenhuis, A. Zendman, E. Vossenaar et al. // Clin. Chim. Acta. -2004. - Vol. 350. - P. 17 - 34.
148.Nishimura, K. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis/ K. Nishimura , D. Sugiyama , Y. Kogata et al.// Ann. Intern. Med. - 2007. - Vol. 146. - P. 797 - 808.
149.Niwa, M. Efficient isolation of cDNA clones encoding rheumatoid arthritis autoantigens by lambda phage surface display/ M. Niwa, K. Fukuoka, T. Fujimoto et al.//J. Biotechnol. -2004. - Vol. 114. - № 2.- P. 55 - 58.
150.Nogueira, L. Performance of two ELISAs for antifilaggrin autoantibodies, using either affinity purified or deiminated recombinant human filaggrin, in the diagnosis of rheumatoid arthritis/ L. Nogueira, M. Sebbag, C. Vincent et al. // Ann. Rheum. Dis. - 2001. - Vol. 60. - P. 882 - 887.
151.Novikov, A.A. Diagnostic value of antibodies against a modified citrullinated vimentin, cyclic citrullinated peptide and IgM rheumatoid factor in early rheumatoid arthritis/ A. A. Novikov, E. N. Alexandrova, D. E. Karateev et al. / Ann. Rheum. Dis.-2007. - Vol. 66. - Suppl. II. - P. 333.
152.Okazaki, Y. Identification of citrullinated eukaryotic translation initiation factor 4G1 as novel autoantigen in rheumatoid arthritis/ Y. Okazaki, A. Suzuki, T. Sawada et al.// Biochem. Biophys. Res. Commun. - 2006. - Vol. 341. - № 1. - P. 94 - 100.
122
153.Ota, F. Activin A induces cell proliferation of fibroblast-like synoviocytes in rheumatoid arthritis/ F. Ota, A. Maeshima, S. Yamashita. et al.// Arthritis Rheum. - 2003. - Vol. 48. - P. 2442 - 2449.
154.Leena, Paimela. Antikeratin antibodies: diagnostic and prognostic markers for early rheumatoid arthritis/ Leena Paimela, Marianne Gripenberg, Pekka Kurki et al. // Annals of the Rheumatic Diseases. - 1992. - Vol. 51. - P. 743 - 746.
155.Pamela, L. Association of autoantibodies to filaggrin with an active disease in early rheumatoid arthritis/ L. Pamela, T. Palosio, K. Aho et al.// Ann. Rheum. Dis. - 2001. - Vol. 60. - P. 32 - 35.
156.Peichl, P. Human neutrophil activating peptide/interleukin 8 acts as an autoantigen in rheumatoid arthritis/ P. Peichl, M. Ceska, H. Broell et al.// Ann. Rheum. Dis. - 1992. - Vol. 51. - № 1. - P. 19 - 22.
157.Polgár, A. Elevated levels of synovial fluid antibodies reactive with the small proteoglycans biglycan and decorin in patients with rheumatoid arthritis or other joint diseases/ A. Polgár, A. Falus, E. Koó et al.// Rheumatology (Oxford). -2003. - Vol. 42. - № 4. - P. 522 - 527.
158.Pramod, Kumar Verma. Comparative Diagnostic Utilities of Anti-keratin Antibody and Anti-CCP2 Antibody in Rheumatoid Arthritis: A Brief Study/ Kumar Verma Pramod, Usha, Anjali, S. K. Saraf //International journal of pharmaceutical science and health care. - 2012. - Vol. 2. - № 1. - P. 32 – 38.
159.Pratesi, F. Deiminated Epstein-Barr virus nuclear antigen 1 is a target of anticitrullinated protein antibodies in rheumatoid arthritis/ F. Pratesi, C. Tommasi, C. Anzilotti et al. //Arthritis Rheum. - 2006. - Vol. 54. - № 3. - P. 733 - 741.
160.Prevoo, M. Modified disease activity scores that include twenty-eight joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis/ M. Prevoo , M. van Hof , H. Kuper // Arthritis Rheum. - 1995. - vol. 38. - P. 44 - 48.
161.Pruijn, G. J. The use of citrullinated peptides and proteins for the diagnosis of rheumatoid arthritis/ G. J. Pruijn, A. Wiik, van W. J. Venrooij // Arthritis Res. Ther. - 2010. - Vol. 12. - № 1. - P. 203.
123
162.Pullerits, R. Synovial fluid expression of autoantibodies specific for RAGE relates to less erosive course of rheumatoid arthritis/ R. Pullerits, M. Bokarewa, L. Dahlberg et al.// Rheumatology (Oxford). -2007. - Vol. 46. - № 8. - P. 1367 -1371.
163.Qin, X. Meta-analysis: diagnostic value of serum anti-mutated citrullinated vimentin antibodies in patients with rheumatoid arthritis/ X. Qin, Y. Deng, J. Xu. et al.//Rheumatol. Int. - 2011. - Vol. 31. - P. 785 - 794.
164.Quinn, M. A. Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcome/ M. A. Quinn, A. K. S. Gough, M. J. Green et al. // Rheumatology. -2006. - vol. 45. - № 4. - P. 478 – 480.
165.Quismorio, F.P. Reactivity of serum antibodies to the keratin layer of rat eophagus in patients with rheumatoid arthritis/ F. P. Quismorio, R. L. Kaufman, T. Beardmore, E. S. Morgan // Arthritis Rheum. - 1983. - Vol. 26. - P. 494 - 949.
166.Rantapaa-Dahlqvist, S. Diagnostic and prognostic significance of autoantibodies in early rheumatoid arthritis/ S. Rantapaa-Dahlqvist //Scandinavian Journal of Rheumatology. -2005. - vol. 34. -№ 2. - P. 83 – 96.
167.Rantapaa-Dahlqvist, S. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis/ S. RantapaaDahlqvist, B. de Jong, E. Berglin et al.//Arthritis. Rheum. - 2003. - Vol. 48. - P. 2741 – 2749.
168.Raptopoulou, A. Anti-citrulline antibodies in the diagnosis and prognosis of rheumatoid arthritis: evolving concepts/ A. Raptopoulou, P. Sidiropoulos, M. Katsouraki, D. T. Boumpas // Critical Reviews in Clinical Laboratory Sciences. - 2007. - vol. 44. - № 4. - P. 339 – 363.
169.Renger, F. Immediate determination of ACPA and rheumatoid factor - a novel point of care test for detection of anti-MCV antibodies and rheumatoid factor using a lateral-flow immunoassay/ F. Renger, H. Bang, E. Feist al. // Arthritis Res. Ther. - 2010. - Vol. 12. - P. 120.
170.Riedemann, J. The use of second generation anti-CCP antibody (anti-CCP2) testing in rheumatoid arthritis—a systematic review/ J. Riedemann, S. Munoz, A.
124
Kavanaugh// Clin. Exp. Rheumatol. -2005. - Vol. 2. - P. 69 – 76.
171.Robert-Pachot, M. A new target for autoantibodies in patients witch rheumatoid arthritis/ M. Robert-Pachot, A. Desbos, A. Moreira et al. // Ann. NY Acad. Sci. - 2007. - Vol. 1108. - P. 382 - 391.
172.Rodrigues-Mahou, M. Association of Anti–Cyclic Citrullinated Peptide and Anti-Sa/Citrullinated Vimentin Autoantibodies in Rheumatoid Arthritis/ M. Rodrigues-Mahou, F. Lopez-Longo, S. Sanchez-Ramon et al.// Arthritis Rheum. (Arthritis Care & Res.). - 2006. - Vol. 55. - № 4. - P. 657 – 561.
173.Rojas-Serrano, J. Very recent onset arthritis: the value of initial rheumatologist evaluation and anti-cyclic citrullinated peptide antibodies in the diagnosis of rheumatoid arthritis./ J. Rojas-Serrano, R. Burgos-Vargas, L. L. Pérez. et al. // Clin. Rheumatol. - 2009. - Vol. 28. - P. 1135 - 1139.
174.Roland, Moll. The human keratins: biology and pathology/ Moll Roland, Divo Markus, Langbein Lutz. // Rheumatology (Oxford). - 2001. - Vol. 35. - № 3. - P. 1224 - 1227.
175.Ronnelid, J. Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression/ J. Ronnelid, M. C. Wick, J. Lampa et al.// Ann. Rheum. Dis. - 2005. - Vol. 64. - P. 1744–1749.
176.Routsias, J. G. Calreticulin synthetic peptide analogues: anti-peptide antibodies in autoimmune rheumatic diseases/ J. G. Routsias, A. G. Tzioufas, M. Sakarellos-Daitsiotis et al. // Clin. Exp. Immunol. - 1993. - Vol. 91. - № 3. - P. 437
– 441.
177.Sakata, M. Autoantibodies to osteopontin in patients with osteoarthritis and rheumatoid arthritis/ M. Sakata, J. I. Tsuruha, K. Masuko-Hongo et al.// J. Rheumatol. - 2001. - Vol. 28. - № 7. - P. 1492 - 1495.
178.Salvador, G. Prevalence and clinical significance of anti-cyclic citrullinated peptide and antikeratin antibodies in palindromic rheumatism. An abortive form of rheumatoid arthritis?/ G. Salvador, A. Gomez, O. Vinas et al. // Rheumatology. - 2003. - Vol. 42. - P. 972 – 975.
125
179.Samuels, J. Impaired early B cell tolerance in patients with rheumatoid arthritis/ J. Samuels, Y.S. Ng, C. Coupillaud et al..//J. Exp. Med. - 2005. - Vol.
201.- P. 1659 - 1667.
180.Schellekens, G. A. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies/ G. A. Schellekens , B. A. de Jong , F. H. van den Hoogen et al. // J. Clin. Invest. - 1998. - Vol. 101. - P. 273 - 281.
181.Schellekens, G. A. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide/ G. A. Schellekens, H. Visser, B. A. de Jong et al. // Arthritis Rheum. - 2000. – Vol .43. - № 1. - P. 55 - 63.
182.Schur, P. Anti-cyclic citrullinated peptide antibodies: diagnostic, predictive, and monitoring value in RA/ P. Schur // Int. J. Adv. Rheumatol. - 2005. - Vol. 3. - № 3. - P. 77 – 83.
183.Sebbag, M. The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies/ M. Sebbag, M. Simon, C. Vincent et al. // J. Clin. Invest. -1995. - vol. 95. - P. 2672 – 2679.
184.Serre, G. Filaggrin (keratin) autoantibodies/ G. Serre, C. Vincent // Autoantibodies. - 1996. - P. 271 - 276.
185.Sghiri, R. Value of antimutated citrullinated vimentin antibodies in diagnosing rheumatoid arthritis/ R. Sghiri, E. Bouajina, D. Bargaoui et al.// Rheumatology International. -2008. - vol. 29. - № 1. - P. 59 – 62.
186.Shankar, S. Role of anti cyclic citrullinated peptide antibodies in erosive disease in patients with rheumatoid arthritis/ S. Shankar, R. Grover, R. Handa// Indian. J. Med. Res. - 2006. -Vol. 124. - P. 689 - 696.
187.Shi, J. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage/ J. Shi, R. Knevel, P. Suwannalai et al.// Proc. Natl. Acad. Sci. USA. - 2011. - Vol. 108. - № 42. - P. 17372 - 17377.
188.Shidara, K. Comparison of the second and third generation anti-cyclic citrullinated peptide antibody assays in the diagnosis of Japanese patients with
126
rheumatoid arthritis/ K. Shidara, E. Inoue, E. Tanaka et al.// Rheumatol. Int. -
2011. - Vol. 31. - № 5. - P. 617 - 622.
189.Shmerling, R. H. The rheumatoid factor: an analysis of clinical utility/ R. H. Shmerling, T. L. Delbanco //Am. J. Med. - 1991. - Vol. 91. - P. 528 - 534.
190.Shmerling, R. H. How useful is the rheumatoid factor? An analysis of sensitivity, specificity, and predictive value/ R.H. Shmerling , T.L. Delbanco // Arch. Intern. Med. - 1992. - Vol. 152. - P. 2417.
191.Simon, M. The cytokeratin filament-aggregating protein filaggrin is the target of the so-called “antikeratin antibodies”, autoantibodies specific for rheumatoid arthritis/ M. Simon, E. Girbal, M. Sebbag et al.// J. Clin. Invest. -1993. - vol. 92. - P. 1387 – 1393.
192.Smolen, J.S. Therapeutic strategies for rheumatoid arthritis/ J. S. Smolen, G. Steiner.// Nat. Rev. Drug. Discov. - 2003. - Vol. 2. - P. 473 - 488.
193.Snijders, G. F. Measurement characteristics of a new rapid anti-CCP2 test compared to the anti-CCP2 ELISA/ G. F. Snijders, A. A. den Broeder, K. Bevers et al.// Scan. J. Rheumatol. - 2008. - Vol. 37. - P. 151 - 154.
194.Snir, O. Autoantibody profiles toward specific citrullinated antigens in serum and synovial fluid of RA patients in Proceedings of the ACR/ O. Snir, M. Widhe, C. von Spee et al. // Annual Scientific Meeting. -2007. - abstract № 1437.
195.Song, Y. W. Autoantibodies in rheumatoid arthritis: rheumatoid factors and anticitrullinated protein antibodies./ Y. W. Song, E. H. Kang //QJM. - 2010. - Vol.
103.- P. 139 - 146.
196.Song, J. S. Comparison of Anti-Mutated Citrullinated Vimentin with AntiCyclic Citrullinated Peptide and Rheumatoid Factors for the Diagnosis of Rheumatoid Arthritis/ J. S. Song, G. B. Park, A. J. Park.// in Proceedings of the ACR: Annual Scientific Meeting. -2007. - abstract № 1893.
197.Soos, L. Clinical Evaluation of Anti-Mutated Citrullinated Vimentin by ELISA in Rheumatoid Arthritis/ L. Soos, Z. Szekanecz, Z. Szabo et al.//The Journal of Rheumatology. - 2007. - Vol. 34. - № 8. - P. 1658 - 1663.
127
198.Souto-Carneiro, M.M. Human monoclonal rheumatoid synovial B lymphocyte hybridoma with a new disease-related specificity for cartilage oligomeric matrix protein/ M. M. Souto-Carneiro, H. Burkhardt, E. C. Müller et al.// J. Immunol. - 2001. - Vol. 166. - № 6. - P. 4202 - 4208.
199.Steinbrocker, O. Therapeutic criteria in rheumatoid arthritis/ O. Steinbrocker, C. Traeger, R. Batterman // J. Amer. Med. Assoc. – 1949. - Vol. 140. - № 8. – P.
659- 662.
200.Steiner, G. Pathogenic and clinical relevance of rheumatoid arthritis associated autoantibodies. From pathogenesis to therapy of autoimmune diseases/ G. Steiner, M. Hoffman // Autoantigens, autoantibodies, autoimmunity. -2009. - Vol. 6. - P. 279 - 295.
201.Suzuki, K. High diagnostic performance of ELISA detection of antibodies to citrullinated antigens in rheumatoid arthritis/ K. Suzuki , T. Sawada , A. Murakami et al.// Scand. J. Rheumatol. - 2003. - Vol. 32. - P. 197 - 204.
202.Swart, A. Third generation anti-citrullinated peptide antibody assay is a sensitive marker in rheumatoid factor negative rheumatoid arthritis/ A. Swart, R. W. Burlingame, I. Gürtler et al.// Clin. Chim. Acta. - 2012. - Vol. 414. - P.266-272.
203.Swedler, W. Routine measurement of IgM, IgG, and IgA rheumatoid factors: high sensitivity, specificity, and predictive value for rheumatoid arthritis/ W. Swedler , J. Wallman , C. J. Froelich , M . Teodorescu // J. Rheumatol. - 1997. - Vol. 24. - P. 1037 - 1044.
204.Syversen, S. W. High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study/ S.W. Syversen , P.I. Gaarder , G. L. Goll et al. // Ann. Rheum. Dis. - 2008. - Vol. 67. - P. 212 - 217.
205.Syversen, S. W. Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10year prospective study/ S. W. Syversen, G. L. Goll, D. van der Heijde et al.// Ann. Rheum. Dis. - 2009. - Vol. 69. - P. 345.
206.Szántó, S. Induction of arthritis in HLA-DR4-humanized and HLA-DQ8-
128
humanized mice by human cartilage proteoglycan aggrecan but only in the presence of an appropriate (non-MHC) genetic background. / S. Szántó, T. Bárdos, Z. Szabó et al.//Arthritis Rheum. - 2004. - Vol. 50. - P. 1984 - 1995.
207.Szekanecz, Z. The INOVA CCP3.1 IGA/IGG ELISA represents significant improvement in the laboratory diagnosis of rheumatoid arthritis/ Z. Szekanecz, J. Tumpek, Z. Szabó et al.// Ann. Rheum. Dis. - 2008. - Vol. 67 (Suppl. II). - P. 568.
208.Taylor, P. A systematic review of serum biomarkers anti-cyclic citrullinated Peptide and rheumatoid factor as tests for rheumatoid arthritis/ P. Taylor ,J. Gartemann , J. Hsieh et al.// Autoimmune. Dis. - 2011. - 815038.
209.Tigh, H. Rheumatoid factor/ H. Tigh, D. Carson // Textbook of rheumatology. - Philadelphia: WB Saunders. - 1997. – P. 241 - 249.
210.Tishler, M. Anti-heat-shock protein antibodies in rheumatic and autoimmune diseases/ M. Tishler, Y. Shoenfeld // Semin. Arthritis Rheum. -1996. - Vol. 26. - №
2.- P. 558 - 563.
211.Turesson, C. Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis/ C. Turesson, L. T. Jacobsson, G. Sturfelt et al.// Ann. Rheum. Dis. - 2007. - Vol. 66. - P. 59 - 64.
212.Uesugi, H. Prevalence and characterization of novel pANCA, antibodies to the high mobility group non-histone chromosomal proteins HMG1 and HMG2, in systemic rheumatic diseases/ H. Uesugi, S. Ozaki, J. Sobajima et al. // J. Rheumatol. - 1998. - Vol. 25. - № 4. - P. 703 - 709.
213.Ukaji, F. Serum samples of patients with rheumatoid arthritis contain a specific autoantibody to "denatured" aldolase A in the osteoblast-like cell line, MG-63/ F. Ukaji, I. Kitajima, T. Kubo et al. //Ann. Rheum. Dis. - 1999. - Vol. 58. - № 3. - P. 169 - 174.
214.Ulrike, Harre. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin/ Harre Ulrike, Georgess,Dan, Bang Holger et al.//J. Clin. Invest. - 2012. - Vol. 122. - № 5. - P. 1791 – 1802.
129
215.Ursum, J. Different properties of ACPA and IgM-RF derived from a large dataset: further evidence o two distinct autoantibody systems/ J. Ursum, W. H. Bos, R. J. van de Stadt et al.// Arthritis Res. Ther. - 2009. - Vol. 11. - P. 7.
216.Ursum, J. Antibodies to mutated citrullinated vimentin and diseaseactivity score in early arthritis: a cohort study/ J. Ursum, M. M. J. Nielen, D. van Schaardenburg et al. // Arthritis Research and Therapy. - 2008. - vol. 10. - № 1. - article R12.
217.Ursum, J. The value of antibodies to mutated citrullinated vimentin in early arthritis/ J. Ursum, D. Schaardenburg, M. Nielen // Ann. Rheum. Dis. - 2007. - Vol. 66. - suppl. 11. - P. 339.
218.Valesini, G. Anticitrullinate antibodies and rheumatoid factors: two distinct autoantibody systems/ G. Valesini, C. Alessandri // Arthritis Res. Ther. - 2009. - Vol. 11. - P. 125.
219.Vallbracht, I. Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis/ I. Vallbracht, J. Rieber, M. Oppermann et al. // Ann. Rheum. Dis. – 2004. - Vol. 63. - № 9. - P. 1079 – 1084.
220.Vallerskog, T. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE/ T. Vallerskog, I. Gunnarsson, M. Widhe et al.// Clin. Immun. - 2007. - Vol. 122. - P. 62 – 74.
221.van Beers, J.J.B.C. Two major classes of rheumatoid arthritis: CCP distinguishes between ACPA-positive and ACPA-negative RA/ J.J.B.C van Beers, W. J. van Venrooij, G. J. M. Pruijn // Autoantigens, autoantibodies, autoimmunity. - 2009. - Vol. 6. - P. 265 - 277.
222.van Boekel, M. A. Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value/ M.A. van Boekel , E.R. Vossenaar , van den F.H. Hoogen , W. J. van Venrooij // Arthritis Res. - 2002. - Vol. 4. - P. 87 - 93.
223.van der Heijde, D.M. How to read radiographs according to the Sharp/van der Heijde method/ D. M. van der Heijde //J. Rheumatol. - 1999. - Vol. 26. - № 3. - P.
743- 745.
130
224.van der Linden, M. P. Value of anti-modified citrullinated vimentin and thirdgeneration anti-cyclic citrullinated peptide compared with second-generation anticyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis/ M. P. van der Linden , D. van der Woude, A. Ioan-Facsinay et al.// Arthritis Rheum. - 2009. - Vol. 60. - P. 2232 - 2241.
225.van Gaalen, F. A. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study/ F. A. van Gaalen, S. P. Linn-Rasker, W. J. van Venrooij et al. // Arthritis Rheum. - 2004. - Vol. 50. - P. 709 – 715.
226.van der Helm-van Mil, A. H. A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: how to guide individual treatment decisions/ A. H. van der Helm-van Mil , S. le Cessie , H. van Dongen et al.// Arthr. Rheum. - 2007. - Vol. 56. - P. 433 - 440.
227.van der Woude, D. Fine specificity of the anti-citrullinated protein antibody response in relationship to the disease course of rheumatoid arthritis/ D. van der Woude, A. Ioan-Facsinay, C. Schwarte et al.// Annals of the Rheumatic Diseases. - 2008. - vol. 67. - suppl. 2. - P. 75.
228.Van Eden, W. Stress, heat shock proteins, and autoimmunity: how immune responses to heat shock proteins are to be used for the control of chronic inflammatory diseases/ W. Van Eden, G. Wick, S. Albani, I. Cohen.// Ann. N Y Acad. Sci. - 2007. - Vol. 1113. - P. 217 - 237.
229.van Leeuwen, M. A.. IgM, IgA, and IgG rheumatoid factors in early rheumatoid arthritis predictive of radiological progression?/ M.A. van Leeuwen , J. Westra, P.L. van Riel et al. // Scand. J. Rheumatol. - 1995. - Vol. 24. - P. 146-153.
230.Van Venrooij, W. J. Anti-CCP antibody, a marker for the early detection of rheumatoid arthritis/ W. J. Van Venrooij, J J. B. C. Van Beers, G. J. M. Pruijn // Annals of the New York Academy of Sciences. - 2008. - vol. 1143. - P. 268 – 285.
231.van Venrooij, W. J. Anti-CCP antibodies: the past, the present and the future/ W. J. van Venrooij, J. J. van Beers, G. J. Pruijn // Nat. Rev. Rheumatol. - 2011. -